Research programme: kinase inhibitors - GPC Biotech/Ingenium
Latest Information Update: 14 Jul 2010
At a glance
- Originator GPC Biotech AG; Ingenium Pharmaceuticals AG
- Mechanism of Action Phosphotransferase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Inflammatory bowel diseases